Holen Sie sich die Stockscreener-App
25.93
0.08%
-0.02
Handel nachbörslich:
25.93
Schlusskurs vom Vortag:
$25.95
Offen:
$26.28
24-Stunden-Volumen:
975.49K
Relative Volume:
0.68
Marktkapitalisierung:
$1.76B
Einnahmen:
$2.76B
Nettoeinkommen (Verlust:
$-358.70M
KGV:
-5.2173
EPS:
-4.97
Netto-Cashflow:
$-35.90M
1W Leistung:
+8.45%
1M Leistung:
-7.23%
6M Leistung:
-36.09%
1J Leistung:
-41.93%
1-Tages-Spanne:
$25.69
$26.55
1-Wochen-Bereich:
$23.20
$27.12
52-Wochen-Spanne:
$22.05
$49.45
Quidelortho Corporation Stock (QDEL) Company Profile
Firmenname
Quidelortho Corporation
Sektor
Branche
Telefon
(858) 552-1100
Adresse
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Vergleichen Sie QDEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
25.93 | 1.84B | 2.76B | -358.70M | -35.90M | -4.97 |
|
ABT
Abbott Laboratories
|
131.75 | 225.22B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 151.88B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.88B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 119.04B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.61B | 5.69B | 1.41B | 577.90M | 6.95 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-09-19 | Fortgesetzt | UBS | Neutral |
| 2024-09-05 | Hochstufung | Craig Hallum | Hold → Buy |
| 2024-03-04 | Herabstufung | UBS | Neutral → Sell |
| 2024-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-14 | Hochstufung | UBS | Sell → Neutral |
| 2022-09-19 | Eingeleitet | Citigroup | Neutral |
| 2022-07-20 | Eingeleitet | UBS | Sell |
| 2022-06-17 | Fortgesetzt | JP Morgan | Neutral |
| 2022-02-22 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-26 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-10-23 | Fortgesetzt | Raymond James | Strong Buy |
| 2018-03-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | Bestätigt | Barclays | Overweight |
| 2018-01-04 | Hochstufung | CL King | Neutral → Buy |
| 2017-09-19 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | Bestätigt | Canaccord Genuity | Hold |
| 2017-02-17 | Eingeleitet | CL King | Neutral |
| 2016-12-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | Bestätigt | Barclays | Overweight |
| 2016-02-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | Bestätigt | Canaccord Genuity | Buy |
| 2015-12-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | Eingeleitet | Barclays | Overweight |
| 2013-07-31 | Bestätigt | Canaccord Genuity | Buy |
| 2011-03-03 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Quidelortho Corporation Aktie (QDEL) Neueste Nachrichten
QuidelOrtho launches certified analyser programme for rural health facilities - Yahoo Finance
QuidelOrtho Launches Certified Analyzer Program to Enhance Diagnostic Access in Rural Areas - AInvest
Is QuidelOrtho's (QDEL) Steadfast Revenue Outlook a Sign of Management Conviction or Overconfidence? - simplywall.st
Visual trend scoring systems applied to QuidelOrtho Corporation2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - Newser
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know - TradingView
QuidelOrtho launches certified analyzer program for rural healthcare - Investing.com
QuidelOrtho launches certified analyzer program for rural healthcare By Investing.com - Investing.com Nigeria
QuidelOrtho's Strategic Expansion in Point-of-Care Diagnostics: A Pathway to Long-Term Value Creation - AInvest
QuidelOrtho Launches Certified Analyzer Program | QDEL Stock News - GuruFocus
QuidelOrtho Launches Certified Analyzer Program to Expand Diagnostic Testing in Underserved Communities - AInvest
QuidelOrtho launches certified analyzer program for underserved areas - StreetInsider
QuidelOrtho Launches Certified Analyzer Program - Barchart.com
The Top 5 Analyst Questions From QuidelOrtho’s Q2 Earnings Call - Yahoo Finance
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - Yahoo Finance
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know | Penticton Herald: Finance - FinancialContent
AI Tools Suggest QuidelOrtho Corporation May Outperform This WeekRisk Managed Intraday Trade Alerts Increase in Volume - 선데이타임즈
Earnings Release: Here's Why Analysts Cut Their QuidelOrtho Corporation (NASDAQ:QDEL) Price Target To US$43.14 - 富途牛牛
Published on: 2025-08-09 08:22:34 - beatles.ru
There's No Escaping QuidelOrtho Corporation's (NASDAQ:QDEL) Muted Revenues Despite A 29% Share Price Rise - 富途牛牛
Will QuidelOrtho's (QDEL) Renewed Cost Discipline Strengthen Its Long-Term Growth Story? - simplywall.st
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
QuidelOrtho narrows China outlook to mid-single-digit growth as cost actions drive margin gains - MSN
QuidelOrtho’s Earnings Call: Mixed Sentiment with Global Growth - The Globe and Mail
QuidelOrtho Topped Estimates But Still Posted A Net Loss - Finimize
QuidelOrtho (QDEL) Analyst Rating Update: UBS Lowers Price Target | QDEL Stock News - GuruFocus
QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand - MSN
UBS Cuts Price Target on QuidelOrtho to $26 From $29, Maintains Neutral Rating - MarketScreener
Should Value Investors Buy QuidelOrtho (QDEL) Stock? - Yahoo Finance
QuidelOrtho 2025 Q2 Earnings Widens Losses Amid Revenue Decline - AInvest
QuidelOrtho Corporation (NASDAQ:QDEL) Q2 2025 Earnings Call Transcript - Insider Monkey
QuidelOrtho Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
QuidelOrtho Q2 Revenue Beats Estimate, EPS Turns Positive Amid Restructuring Costs. - AInvest
QuidelOrtho Q2 2025 Earnings: Adjusted EPS Beats Estimates, Revenue Hits $614 Million - AInvest
Citigroup Reiterates Buy on QuidelOrtho, PT Lowered to $40 - AInvest
QuidelOrtho (QDEL) Fiscal Q2 EPS Beats - AOL.com
QuidelOrtho shares rise 14.02% premarket after reporting Q2 earnings with improved EBITDA margin and cost savings. - AInvest
QuidelOrtho Stock Soars 10.85% on Q2 Earnings Beat - AInvest
Citi Adjusts QuidelOrtho (QDEL) Price Target, Maintains Buy Rati - GuruFocus
QuidelOrtho 2025 Q2 Earnings Deeper Losses Amid Revenue Decline - AInvest
QuidelOrtho revenue decreases to USD 614M in Q2 2025 - Medical Buyer
QuidelOrtho: Q2 Earnings Snapshot - Huron Daily Tribune
QuidelOrtho Corp SEC 10-Q Report - TradingView
QuidelOrtho's Q2 Financial Performance and Future OutlookNews and Statistics - IndexBox
QuidelOrtho's Strategic Cost-Cutting and Margin Expansion: A Hidden Opportunity in a Declining Revenue Environment? - AInvest
QuidelOrtho Fiscal Q2 Swings to Adjusted Earnings, Revenue Falls - MarketScreener
QuidelOrtho Corp (QDEL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance
QuidelOrtho Corp (QDEL) Q2 2025 Earnings Call Highlights: Naviga - GuruFocus
QuidelOrtho Corp (QDEL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... By GuruFocus - Investing.com Canada
QuidelOrtho's 2025 Q2 Earnings Call: Key Contradictions in COVID Revenue, Tariffs, and China Growth - AInvest
QuidelOrtho Corporation 2025 Q2ResultsEarnings Call Presentation (NASDAQ:QDEL) - Seeking Alpha
QuidelOrtho (QDEL) Fiscal Q2 EPS Beats - The Motley Fool
Finanzdaten der Quidelortho Corporation-Aktie (QDEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.74%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):